The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Association between Staphylococcus aureus alone or combined with Pseudomonas aeruginosa and the clinical condition of patients with cystic fibrosis
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, due to repeated antibiotic therapy, CF patients also carry higher levels of methicillin-resistant S. aureus (MRSA) that is associated with a worse lung function compared to methicillin- sensitive S. aureus (MSSA) but only in combination with P. aeruginosa (Hubert et al., 2013).”
From In vivo and In vitro Interactions between Pseudomonas aeruginosa and Staphylococcus spp. (2017) · cites this paper as Hubert et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis
Welsh, M. J., & Smith, A. E. (1993) · Cell · doi:10.1016/0092-8674(93)90353-r · Cited by 1,485
Research works printed but not linked: 21
- Goss, 2011, Staphylococcus aureus and MRSA in cystic fibrosis, J Cyst Fibros, 10, 298, 10.1016/j.jcf.2011.06.002 · DOI · Paper page
- Kahl, 2010, Impact of Staphylococcus aureus on the pathogenesis of chronic cystic fibrosis lung disease, Int J Med Microbiol, 300, 514, 10.1016/j.ijmm.2010.08.002 · DOI
- Stone, 2007, Update on the epidemiology and management of Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, in patients with cystic fibrosis, Curr Opin Pulm Med, 13, 515, 10.1097/MCP.0b013e3282efbbac · DOI
- Dasenbrook, 2011, Update on methicillin-resistant Staphylococcus aureus in cystic fibrosis, Curr Opin Pulm Med, 17, 437, 10.1097/MCP.0b013e32834b95ed · DOI
- Emerson, 2002, Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis, Pediatr Pulmonol, 34, 91, 10.1002/ppul.10127 · DOI · Paper page
- Courtney, 2007, Predictors of mortality in adults with cystic fibrosis, Pediatr Pulmonol, 42, 525, 10.1002/ppul.20619 · DOI · Paper page
- Gibson, 2003, Pathophysiology and management of pulmonary infections in cystic fibrosis, Am J Respir Crit Care Med, 168, 918, 10.1164/rccm.200304-505SO · DOI · Paper page
- Ren, 2007, Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function, Pediatr Pulmonol, 42, 513, 10.1002/ppul.20604 · DOI
- Dasenbrook, 2008, Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis, Am J Respir Crit Care Med, 178, 814, 10.1164/rccm.200802-327OC · DOI · Paper page
- Dasenbrook, 2010, Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis, JAMA, 303, 2386, 10.1001/jama.2010.791 · DOI · Paper page
- Hauser, 2011, Clinical significance of microbial infection and adaptation in cystic fibrosis, Clin Microbiol Rev, 24, 29, 10.1128/CMR.00036-10 · DOI · Paper page
- Burns, 1998, Microbiology of sputum from patients at cystic fibrosis centers in the United States, Clin Infect Dis, 27, 158, 10.1086/514631 · DOI · Paper page
- Muhlebach, 2011, Treatment intensity and characteristics of MRSA infection in cystic fibrosis, J Cyst Fibros, 10, 201, 10.1016/j.jcf.2011.02.004 · doi:10.1016/j.jcf.2011.02.004
- Huang, 1987, Clinical features, survival rate, and prognostic factors in young adults with cystic fibrosis, Am J Med, 82, 871, 10.1016/0002-9343(87)90147-1 · DOI
- Liou, 2001, Predictive 5-year survivorship model of cystic fibrosis, Am J Epidemiol, 153, 345, 10.1093/aje/153.4.345 · DOI · Paper page
- Navarro, 2001, Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF, Eur Respir J, 18, 298, 10.1183/09031936.01.00068901 · DOI · Paper page
- Vanderhelst, 2012, Prevalence and impact on FEV1 decline of chronic methicillin-resistant Staphylococcus aureus (MRSA) colonization in patients with cystic fibrosis. A single-center, case control study of 165 patients, J Cyst Fibros, 11, 2, 10.1016/j.jcf.2011.08.006 · DOI
- Sawicki, 2008, The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis, Pediatr Pulmonol, 43, 1117, 10.1002/ppul.20914 · DOI
- Rosenbluth, 2004, Lung function decline in cystic fibrosis patients and timing for lung transplantation referral, Chest, 126, 412, 10.1378/chest.126.2.412 · DOI
- Hudson, 1993, Prognostic implications of initial oropharyngeal bacterial flora in patients with cystic fibrosis diagnosed before the age of two years, J Pediatr, 122, 854, 10.1016/S0022-3476(09)90007-5 · DOI
- Sagel, 2009, Impact of Pseudomonas and staphylococcal infection on inflammation and clinical status in young children with cystic fibrosis, J Pediatr, 154, 183, 10.1016/j.jpeds.2008.08.001 · DOI · Paper page
Cited by
Phytochemicals for human disease: An update on plant-derived compounds antibacterial activity
Barbieri, R., Coppo, E., Marchese, A., Daglia, M., Sobarzo-Sánchez, E., Nabavi, S. F., & Nabavi, S. M. (2017) · Microbiological Research · doi:10.1016/j.micres.2016.12.003 · Cited by 669
In vivo and In vitro Interactions between Pseudomonas aeruginosa and Staphylococcus spp.
Hotterbeekx, A., Kumar-Singh, S., Goossens, H., & Malhotra-Kumar, S. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00106 · Cited by 289
Hammer, N. D., Cassat, J. E., Noto, M. J., Lojek, L. J., Chadha, A. D., Schmitz, J. E., Creech, C. B., & Skaar, E. P. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.09.002 · Cited by 72
Metadata
- Authors
- Hubert, D., Réglier-Poupet, H., Sermet-Gaudelus, I., Ferroni, A., Le Bourgeois, M., Burgel, P.-R., Serreau, R., Dusser, D., Poyart, C., & Coste, J.
- Venue
- Journal of Cystic Fibrosis
- Publisher
- Elsevier BV
- Published
- 2013-09
- Volume
- 12
- Issue
- 5
- Pages
- 497-503
- ISSN
- 1569-1993
- Cited by
- 121
- References
- 1
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 730 d)
- Funders
- French CF Association Vaincre la Mucoviscidose
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.